{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T10:53:35Z","timestamp":1782298415856,"version":"3.54.5"},"reference-count":20,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["24-0824"],"award-info":[{"award-number":["24-0824"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_pp-2025-0035_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The effects of preoperative chemotherapy have been poorly studied in colorectal cancer with peritoneal metastases (CRC-PM). This study evaluated preoperative chemotherapy from the first multi-disciplinary team meeting (MDT) decision, focusing on the response rates, surgical outcomes, and survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2025-0035_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study analyzed consecutive patients with resectable or potentially resectable CRC-PM evaluated at Uppsala University Hospital\u2019s peritoneal-MDT between March 2019 and December 2023. Kaplan\u2013Meier curves and Cox-regression analyses were used for survival analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2025-0035_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 179 patients, 81 underwent upfront surgery; 52 received doublet chemotherapy and 46 received doublet with targeted therapy. Targeted group showed a 52\u202f% overall response rate vs. 36\u202f% for doublet group (p=0.14), with patients selected for CRS and HIPEC at a 52\u202f% vs. 31\u202f% rate, respectively, p=0.086. The median overall survival was superior in the targeted group than in the doublet group (intention-to-treat with all patients included): 21 (95\u202f%CI: 18\u201335) vs. 17 (95\u202f%CI: 14\u201322) months (p=0.027). The VEGF-targeted therapy outperformed EGFR-targeted therapy: 32 (95\u202f%CI: 21-Not reached) vs. 15 (95\u202f%CI: 11\u201340) months (p=0.042).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2025-0035_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Preoperative chemotherapy with targeted antibodies improves overall survival in CRC-PM in patients that are not candidates for upfront CRS and HIPEC. Bevacizumab is associated with improvement over EGFR targeted treatment in a subgroup analysis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/pp-2025-0035","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T03:58:01Z","timestamp":1765339081000},"page":"1-10","source":"Crossref","is-referenced-by-count":1,"title":["Preoperative chemotherapy in colorectal peritoneal metastatic disease\u00a0\u2013\u00a0a real-world observational cohort study"],"prefix":"10.1515","volume":"11","author":[{"given":"Peter H.","family":"Cashin","sequence":"first","affiliation":[{"name":"Department of Surgery and Urology , 8097 Uppsala University Hospital , Uppsala , Sweden"},{"name":"Department of Surgical Sciences , Uppsala University , Uppsala , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petter","family":"Fr\u00fchling","sequence":"additional","affiliation":[{"name":"Department of Surgery and Urology , 8097 Uppsala University Hospital , Uppsala , Sweden"},{"name":"Department of Surgical Sciences , Uppsala University , Uppsala , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pontus","family":"Gr\u00f6nlund","sequence":"additional","affiliation":[{"name":"Department of Surgery and Urology , 8097 Uppsala University Hospital , Uppsala , Sweden"},{"name":"Department of Surgical Sciences , Uppsala University , Uppsala , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilhelm","family":"Graf","sequence":"additional","affiliation":[{"name":"Department of Surgery and Urology , 8097 Uppsala University Hospital , Uppsala , Sweden"},{"name":"Department of Surgical Sciences , Uppsala University , Uppsala , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Nygren","sequence":"additional","affiliation":[{"name":"Department of Oncology , Uppsala University Hospital , Uppsala , Sweden"},{"name":"Department of Immunology, Genetics and Pathology , Uppsala University , Uppsala , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6513-8228","authenticated-orcid":false,"given":"Lana","family":"Ghanipour","sequence":"additional","affiliation":[{"name":"Department of Surgery and Urology , 8097 Uppsala University Hospital , Uppsala , Sweden"},{"name":"Department of Surgical Sciences , Uppsala University , Uppsala , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"2026050315471968540_j_pp-2025-0035_ref_001","doi-asserted-by":"crossref","unstructured":"Morgan, E, Arnold, M, Gini, A, Lorenzoni, V, Cabasag, CJ, Laversanne, M, et al.. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut 2023;72:338\u201344. https:\/\/doi.org\/10.1136\/gutjnl-2022-327736.","DOI":"10.1136\/gutjnl-2022-327736"},{"key":"2026050315471968540_j_pp-2025-0035_ref_002","doi-asserted-by":"crossref","unstructured":"Franko, J, Shi, Q, Meyers, JP, Maughan, TS, Adams, RA, Seymour, MT, et al.. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the analysis and research in cancers of the digestive system (ARCAD) database. Lancet Oncol 2016;17:1709\u201319. https:\/\/doi.org\/10.1016\/s1470-2045(16)30500-9.","DOI":"10.1016\/S1470-2045(16)30500-9"},{"key":"2026050315471968540_j_pp-2025-0035_ref_003","doi-asserted-by":"crossref","unstructured":"Franko, J, Shi, Q, Goldman, CD, Pockaj, BA, Nelson, GD, Goldberg, RM, et al.. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J\u00a0Clin Oncol 2012;30:263\u20137. https:\/\/doi.org\/10.1200\/jco.2011.37.1039.","DOI":"10.1200\/JCO.2011.37.1039"},{"key":"2026050315471968540_j_pp-2025-0035_ref_004","doi-asserted-by":"crossref","unstructured":"Cashin, PH, Mahteme, H, Sp\u00e5ng, N, Syk, I, Fr\u00f6din, JE, Torkzad, M, et al.. Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: a randomised trial. Eur J Cancer 2016;53:155\u201362. https:\/\/doi.org\/10.1016\/j.ejca.2015.09.017.","DOI":"10.1016\/j.ejca.2015.09.017"},{"key":"2026050315471968540_j_pp-2025-0035_ref_005","doi-asserted-by":"crossref","unstructured":"Verwaal, VJ, van Ruth, S, de Bree, E, van Slooten, GW, van Tinteren, H, Boot, H, et al.. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J\u00a0Clin Oncol 2003;21:3737\u201343. https:\/\/doi.org\/10.1200\/jco.2003.04.187.","DOI":"10.1200\/JCO.2003.04.187"},{"key":"2026050315471968540_j_pp-2025-0035_ref_006","doi-asserted-by":"crossref","unstructured":"Qu\u00e9net, F, Elias, D, Roca, L, Go\u00e9r\u00e9, D, Ghouti, L, Pocard, M, et al.. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2021;22:256\u201366. https:\/\/doi.org\/10.1016\/s1470-2045(20)30599-4.","DOI":"10.1016\/S1470-2045(20)30599-4"},{"key":"2026050315471968540_j_pp-2025-0035_ref_007","doi-asserted-by":"crossref","unstructured":"Cashin, PH, Esquivel, J, Larsen, SG, Liauw, W, Alzahrani, NA, Morris, DL, et al.. Perioperative chemotherapy in colorectal cancer with peritoneal metastases: a global propensity score matched study. eClinicalMedicine 2022;55:101746. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101746.","DOI":"10.1016\/j.eclinm.2022.101746"},{"key":"2026050315471968540_j_pp-2025-0035_ref_008","doi-asserted-by":"crossref","unstructured":"Flood, MP, Kong, JCH, Wilson, K, Mohan, H, Waters, PS, McCormick, JJ, et al.. The impact of neoadjuvant chemotherapy on the surgical management of colorectal peritoneal metastases: a systematic review and meta-analysis. Ann Surg Oncol 2022;29:6619\u201331. https:\/\/doi.org\/10.1245\/s10434-022-11699-7.","DOI":"10.1245\/s10434-022-11699-7"},{"key":"2026050315471968540_j_pp-2025-0035_ref_009","doi-asserted-by":"crossref","unstructured":"van den Heuvel, TBM, Lurvink, RJ, Rovers, KPB, van Hellemond, IEG, de Hingh, IHJT. Systemic chemotherapy in addition to CRS-HIPEC for colorectal peritoneal metastases: a critical systematic review on the impact on overall survival. J\u00a0Surg Oncol 2024;130:1378\u201389. https:\/\/doi.org\/10.1002\/jso.27849.","DOI":"10.1002\/jso.27849"},{"key":"2026050315471968540_j_pp-2025-0035_ref_010","doi-asserted-by":"crossref","unstructured":"Tomasello, G, Petrelli, F, Ghidini, M, Russo, A, Passalacqua, R, Barni, S. FOLFOXIRI plus bevacizumab as conversion therapy for patients with initially unresectable metastatic colorectal cancer: a systematic review and pooled analysis. JAMA Oncol 2017;3:e170278. https:\/\/doi.org\/10.1001\/jamaoncol.2017.0278.","DOI":"10.1001\/jamaoncol.2017.0278"},{"key":"2026050315471968540_j_pp-2025-0035_ref_011","doi-asserted-by":"crossref","unstructured":"Razenberg, LG, van Gestel, YR, Lemmens, VE, de Hingh, IH, Creemers, GJ. Bevacizumab in addition to palliative chemotherapy for patients with peritoneal carcinomatosis of colorectal origin: a nationwide population-based study. Clin Colorectal Cancer 2016;15:e41\u20136. https:\/\/doi.org\/10.1016\/j.clcc.2015.12.006.","DOI":"10.1016\/j.clcc.2015.12.006"},{"key":"2026050315471968540_j_pp-2025-0035_ref_012","doi-asserted-by":"crossref","unstructured":"Dietz, MV, Ziekman, MJ, van Kooten, JP, Brandt-Kerkhof, ARM, van Meerten, E, Verhoef, C, et al.. Treatment and survival outcomes for patients with colorectal peritoneal metastases deemed ineligible for cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC): results of a retrospective study. Ann Surg Oncol 2023;30:2048\u201356. https:\/\/doi.org\/10.1245\/s10434-022-12969-0.","DOI":"10.1245\/s10434-022-12969-0"},{"key":"2026050315471968540_j_pp-2025-0035_ref_013","doi-asserted-by":"crossref","unstructured":"Rovers, KP, Bakkers, C, Nienhuijs, SW, Burger, JWA, Creemers, GJM, Thijs, AMJ, et al.. Perioperative systemic therapy vs cytoreductive surgery and hyperthermic intraperitoneal chemotherapy alone for resectable colorectal peritoneal metastases: a phase 2 randomized clinical trial. JAMA Surg 2021;156:710\u201320. https:\/\/doi.org\/10.1001\/jamasurg.2021.1642.","DOI":"10.1001\/jamasurg.2021.1642"},{"key":"2026050315471968540_j_pp-2025-0035_ref_014","doi-asserted-by":"crossref","unstructured":"Rovers, KP, Bakkers, C, Simkens, GAAM, Burger, JWA, Nienhuijs, SW, Creemers, GJM, et al.. Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6). BMC Cancer 2019;19:390. https:\/\/doi.org\/10.1186\/s12885-019-5545-0.","DOI":"10.1186\/s12885-019-5545-0"},{"key":"2026050315471968540_j_pp-2025-0035_ref_015","doi-asserted-by":"crossref","unstructured":"Eveno, C, Passot, G, Go\u00e9r\u00e9, D, Soyer, P, Gayat, E, Glehen, O, et al.. Bevacizumab doubles the early postoperative complication rate after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 2014;21:1792\u2013800. https:\/\/doi.org\/10.1245\/s10434-013-3442-3.","DOI":"10.1245\/s10434-013-3442-3"},{"key":"2026050315471968540_j_pp-2025-0035_ref_016","doi-asserted-by":"crossref","unstructured":"Laoukili, J, Constantinides, A, Wassenaar, ECE, Elias, SG, Raats, DAE, van Schelven, SJ, et al.. Peritoneal metastases from colorectal cancer belong to consensus molecular subtype 4 and are sensitised to oxaliplatin by inhibiting reducing capacity. Br J Cancer 2022;126:1824\u201333. https:\/\/doi.org\/10.1038\/s41416-022-01742-5.","DOI":"10.1038\/s41416-022-01742-5"},{"key":"2026050315471968540_j_pp-2025-0035_ref_017","doi-asserted-by":"crossref","unstructured":"Ubink, I, van Eden, WJ, Snaebjornsson, P, Kok, NFM, van Kuik, J, van Grevenstein, WMU, et al.. Histopathological and molecular classification of colorectal cancer and corresponding peritoneal metastases. Br J Surg 2018;105:e204\u201311. https:\/\/doi.org\/10.1002\/bjs.10788.","DOI":"10.1002\/bjs.10788"},{"key":"2026050315471968540_j_pp-2025-0035_ref_018","doi-asserted-by":"crossref","unstructured":"Ten Hoorn, S, de Back, TR, Sommeijer, DW, Vermeulen, L. Clinical value of consensus molecular subtypes in colorectal cancer: a systematic review and meta-analysis. J\u00a0Natl Cancer Inst 2022;114:503\u201316. https:\/\/doi.org\/10.1093\/jnci\/djab106.","DOI":"10.1093\/jnci\/djab106"},{"key":"2026050315471968540_j_pp-2025-0035_ref_019","doi-asserted-by":"crossref","unstructured":"Wilson, RB. Hypoxia, cytokines and stromal recruitment: parallels between pathophysiology of encapsulating peritoneal sclerosis, endometriosis and peritoneal metastasis. Pleura Peritoneum 2018;3:20180103. https:\/\/doi.org\/10.1515\/pp-2018-0103.","DOI":"10.1515\/pp-2018-0103"},{"key":"2026050315471968540_j_pp-2025-0035_ref_020","unstructured":"Rovers, K, Bakkers, C, Marijn van den Heuvel, TB, Van deVlasakker, V, Tuynman, JB, Aalbers, A, Boerma, D, et al.. Perioperative systemic therapy for resectable colorectal peritoneal metastases: a multicenter randomized phase 3 trial (CAIRO6). Chicago, Illinois, USA: ASCO Abstract. https:\/\/www.asco.org\/abstracts-presentations\/ABSTRACT484340."}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2025-0035\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2025-0035\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T20:59:42Z","timestamp":1777841982000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2025-0035\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12,16]]},"published-print":{"date-parts":[[2026,3,19]]}},"alternative-id":["10.1515\/pp-2025-0035"],"URL":"https:\/\/doi.org\/10.1515\/pp-2025-0035","relation":{},"ISSN":["2364-7671","2364-768X"],"issn-type":[{"value":"2364-7671","type":"print"},{"value":"2364-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,11]]}}}